Lung (small cell) cancer Cancer Malignant neoplasm of bronchus or lung
Conditions
Interventions
1. ECMV Regimen: Three courses three weeks apart of Etoposide, Cyclophosphamide, Methotrexate and Vincristine.
2. EV Regimen: Three courses three weeks apart of Etoposide and Vincristi
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Primarily untreated microscopically confirmed SCLC 2. Age <80 3. Limited disease: poor performance status (World Health Organisation [WHO] grade 3 or 4). Extensive disease: performance status any grade 4. Renal function normal 5. Plasma Billirubin not greater than twice normal levels
Exclusion criteria
Exclusion criteria: 1. Previous anticancer treatment for current SCLC 2. Presence of other malignant disease (except previous basal cell carcinoma or in situ carcinoma of the cervix) 3. Presence of other serious condition contraindicating the study regimens
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Added 05/08/09: 1. Palliation of symptoms 2. Toxicity 3. Performance status 4. Quality of life 5. Response rate Initial outcome measures not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed